Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Abhishek Tripathi, Yu-Hui Chen, David Frazier Jarrard, Noah M. Hahn, Jorge A. Garcia, Robert Dreicer, Glenn Liu, Maha H. A. Hussain, Daniel H. Shevrin, Matthew M. Cooney, Mario A. Eisenberger, Manish Kohli, Elizabeth R. Plimack, Nicholas J. Vogelzang, Joel Picus, Michael Anthony Carducci, Robert S. DiPaola, Christopher Sweeney
Institutions: OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Dana-Farber Cancer Institute, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Johns Hopkins University, Johns Hopkins Medicine, University Hospitals of Cleveland, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, University of Virginia Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Endeavor Health, Sidney Kimmel Comprehensive Cancer Center, Huntsman Cancer Institute, Fox Chase Cancer Center, Comprehensive Cancer Centers of Nevada, Washington University in St. Louis, University of Kentucky
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281878320